Chitosan Nanoparticles for Antiviral Drug Delivery: A Novel Route for COVID-19 Treatment

9Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Chitosan has been investigated in several biological fields, including drug and gene delivery, tissue engineering antiviral and immunological adjuvant methods. It’s a cationic copolymer of N-acetyl glucosamine and D-glucosamine with different molecular chain lengths, compositions, and sequences than N-acetyl glucosamine and D-glucosamine. It is biocompatible and cyto-compatible, as well as recyclable and bioresorbable. As effective drug delivery methods, chitosan nanoparticles are shaped into several pathways. The purpose of this article is to provide an overview of its antiviral application as a nanocarrier for antiviral medications, highlighting the benefits, limitations, and downsides. In this review, we will report the most recent COVID-19 vaccination advances. It will also be discussed what the future holds for chitosan nanoparticles in the treatment of coronaviruses.

Cite

CITATION STYLE

APA

Safer, A. M., & Leporatti, S. (2021). Chitosan Nanoparticles for Antiviral Drug Delivery: A Novel Route for COVID-19 Treatment. International Journal of Nanomedicine. Dove Medical Press Ltd. https://doi.org/10.2147/IJN.S332385

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free